Corporate Profile 47Billion Information Technology
Partnering In Pharmaceutical Latin American Markets
1. Partnering in Latin American markets Finding the perfect licensing alliance between Generics / R&D Giovanny León, BD&L Director Vienna, 12 th June 2009
2. LatAm current & future potential Venezuela: the LatAm fastest growth driver LatAm In-licensing business needs Generics / R&D licensing alliances opps. Agenda
3.
4. IMS forecasts Venezuela to achieve by 2013 the 11th position in worldwide ranking following Brazil Source: IMS Health Market Prognosis, Mar 2009. Market size ranking in Constant US$. *Russia 2013 Market Insights estimate 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 Russia Belgium Netherlands Poland Greece Australia South Korea India Turkey Mexico Brazil Canada Spain United Kingdom Italy China Germany France Japan United States 2008 Rank United States United States 1 Turkey Australia 12 Venezuela Mexico 11 United Kingdom Brazil 10 Canada China 9 Brazil Canada 8 Italy Spain 7 Spain 6 France Italy 5 South Korea Netherlands 15 Mexico Poland 14 India India 13 Germany France 4 China Germany 3 Greece South Korea 17 Russia* Belgium 16 Japan Japan 2 Netherlands Greece 20 Australia Portugal 19 Poland Turkey 18 2013 Rank 2003 Rank Netherlands Greece South Korea Turkey Brazil Spain Italy Germany Japan Turkey United Kingdom Brazil Spain United Kingdom Mexico Germany France Russia* Japan Japan Netherlands Poland 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
5. Venezuela have become the LatAm growth driver LATIN AMERICA PHARMACEUTICAL MARKET SALES AND GROWTH Mat Apr 2009 (US$ Const.) Share of Value Sales $37.9 Bn Share of Value Growth $1.5 Bn Source: IMS Health, PM, MAT Apr 2009, Retail Channel Retail only
6. Venezuela accelerates growth, while Brazil breaches the gap with Mexico Source: IMS, MAT April 2009, Retail Channel 12,48% 103 6,99% 1,8% 692 Perú 9,85% 108 12,08% 2,1% 807 Ecuador 7,64% 94 -2,68% 2,6% 993 Chile 10,15% 102 6,16% 3,4% 1.284 Centro América 7,54% 94 -1,90% 4,3% 1.623 Colombia 12,38% 112 16,64% 10,1% 3.822 Argentina 23,12% 127 31,91% 14,5% 5.491 Venezuela 3,25% 87 -9,87% 24,6% 9.324 México 17,17% 99 3,45% 36,6% 13.883 Brasil 11,70% 100 4,01% 100,0% 37.919 LatAm CAGR Mat Apr 05-09 Evol. Ix Growth MS% Sales Mat 09/Apr
7. Volume is the major driver of growth in most markets representing a healthy opportunity; Mexico shows high price growth Source: IMS Health, MIDAS, MAT December 2007 % contribution to growth constant US$ % GROWTH CONSTANT US$ Venezuela’s inflation >25% is a major factor in price growth LATIN AMERICA: ELEMENTS OF GROWTH % 2007 -5% 0% 5% 10% 15% 20% 25% 30% 35% LA MXC BRZ ARG VNZ COL CHL CA ECU PER Price Volume & Mix New elements Retail only 12.0% 7.5% 9.9% 19.1% 33.0% 2.4% 16.7% 7.5% 13.5% 18.4%
10. Latin America is forecasted to continue with double digit growth, mainly powered by Venezuela and Argentina Source: IMS Health, IMS Market Prognosis International, Mar 2008 11,5% 9,9% Latin America 26,7% 27,6% Venezuela 8,8% 9,2% Peru 7,4% 7,2% Mexico 8,8% 4,3% Colombia 7,4% 4,6% Chile 9,7% 9,5% Brazil 13,7% 12,9% Argentina CAGR 2007-2012 CAGR 2003-2007 Country
11. LatAm current & future potential Venezuela: the LatAm fastest growth driver LatAm In-licensing business needs Generics / R&D licensing alliances opps. Agenda
12.
13.
14.
15. LatAm current & future potential Venezuela: the LatAm fastest growth driver LatAm In-licensing business needs Generics / R&D licensing alliances opps. Agenda
16.
17.
18.
19. LatAm current & future potential Venezuela: the LatAm fastest growth driver LatAm In-licensing business needs Generics / R&D licensing alliances opps. Agenda
We believe our portfolio best meets the varied and often complex needs of patients and societies. Novartis is positioned to lead in innovation, partner with others and offer solutions to patients across a broad healthcare spectrum.
We believe our portfolio best meets the varied and often complex needs of patients and societies. Novartis is positioned to lead in innovation, partner with others and offer solutions to patients across a broad healthcare spectrum.